Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.74% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Sep 30, 2024
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-123423General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-58.29% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
22.46% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
25.75% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
64.11% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-70.27% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
52.04% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
29.12% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 4.00%
- Current
- 0.74%
- Delta
- -3.26%
- Previous
- -40.06%
- Current
- -58.29%
- Delta
- -18.22%
- Previous
- -11.72%
- Current
- 22.46%
- Delta
- 34.18%
- Previous
- 30.59%
- Current
- 25.75%
- Delta
- -4.85%
- Previous
- 55.27%
- Current
- 64.11%
- Delta
- 8.83%
- Previous
- -109.56%
- Current
- -70.27%
- Delta
- 39.28%
- Previous
- 58.70%
- Current
- 52.04%
- Delta
- -6.66%
- Previous
- 30.00%
- Current
- 29.12%
- Delta
- -0.88%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Analogous To · ADPT state analogue 3 →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_DECREASED →Transitioned To · ADPT CASH_GENERATION_DECREASED →Transitioned To · ADPT GROWTH_INCREASED →Transitioned To · ADPT INVENTORY_PRESSURE_DECREASED →Transitioned To · ADPT MARGIN_INCREASED →Transitioned To · ADPT PROFITABILITY_INCREASED →Transitioned To · ADPT R_AND_D_INTENSITY_DECREASED →Transitioned To · ADPT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.